var data={"title":"North American coral snake (Micrurus fulvius) antivenom: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">North American coral snake (Micrurus fulvius) antivenom: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5657?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=north-american-coral-snake-micrurus-fulvius-antivenom-patient-drug-information\" class=\"drug drug_patient\">see &quot;North American coral snake (Micrurus fulvius) antivenom: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13265238\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Expiration Dating for Antivenin (Micrurus fulvius): Update</span>\n      <span class=\"collapsible-date\">January 2018</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">Wyeth Pharmaceuticals no longer manufactures Antivenin (<i>Micrurus fulvius</i>) (Equine Origin), and there is no alternative product licensed in the U.S. for coral snake envenomation. There is currently one lot of Antivenin (<i>Micrurus fulvius</i>) (Equine Origin) available for use: Lot number L67530, with an expiration date extended through January 31, 2019.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Institutions should retain any remaining inventory of lot number L67530 until the aforementioned expiration date. Clinicians should note that due to supply concerns, Pfizer, Inc supplies product only to direct customers on a replacement or emergency basis. To obtain antivenin, Pfizer, Inc may be reached at 800-666-7248; alternatively, clinicians may contact their local Poison Control Center at 800-222-1222 for assistance in locating antivenin. In the event licensed antivenin cannot be secured, an investigational imported antivenin may be available under an Investigational New Drug (IND) protocol with informed consent; for more information contact a local Poison Control Center at 800-222-1222 or the U.S. Food and Drug Administration (FDA) at 800-835-4709 (business hours) or 301-796-8240 (nonbusiness hours).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136142\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antivenin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136133\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sensitivity testing:</b> Intradermal skin test should be performed prior to antivenin administration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Skin test: Intradermal: </i>0.02 to 0.03 mL of a 1:10 dilution of normal horse serum or antivenin; evaluate against a control test (intradermal injection of NS on the opposite extremity). A 1:100 or greater dilution should be used if the patient&rsquo;s history suggests hypersensitivity. <b>Note:</b> A positive reaction is an urticarial wheal with or without pseudopodia surrounded by a zone of erythema appearing within 5 to 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Desensitization:</b> <b>Note:</b> In separate vials or syringes, prepare 1:10 and 1:100 dilutions of antivenin in NS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Inject 0.1 mL, 0.2 mL, and 0.5 mL of the 1:100 dilution at 15-minute intervals. During this procedure, proceed with the next dose only if a reaction has NOT occurred following the previous dose. Repeat the procedure using the 1:10 dilution and then undiluted antivenin. If no reaction has occurred following administration of 0.5 mL of undiluted antivenin, switch to IM administration and continue doubling the dose at 15-minute intervals until the entire dose has been administered or administer the usual IV dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1 mg/mL) proximal to the tourniquet or into another extremity. Wait at least 30 minutes; then administer another antivenin injection at the previous dilution which did not evoke a reaction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Micrurus fulvius </i></b> <b>(Eastern coral snake) or</b> <b><i>M. tener </i></b> <b>(Texas coral snake) envenomation:</b>  IV: 30 to 50 mL (3 to 5 vials) by slow injection (dependent on severity of signs/symptoms; some patients may need more than 10 vials).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Each vial of antivenom neutralizes ~2 mg of venom.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136139\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sensitivity testing:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Desensitization:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Micrurus fulvius </i>(Eastern coral snake) or</b> <b><i>M. tener </i>(Texas coral snake) envenomation: </b>  Children and Adolescents: IV: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136134\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673205\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15673206\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136122\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic:  (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136110\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49488306\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Clinicians should note that due to supply concerns, Pfizer, Inc supplies product only to direct customers on a replacement or emergency basis. To obtain antivenin, Pfizer, Inc may be reached at 800-666-7248; alternatively, clinicians may contact their local Poison Control Center at 800-222-1222 for assistance in locating antivenin. In the event licensed antivenin cannot be secured, an investigational imported antivenin may be available under an Investigational New Drug (IND) protocol with informed consent; for more information contact a local Poison Control Center at 800-222-1222 or the US Food and Drug Administration (FDA) at 800-835-4709 (business hours) or 301-796-8240 (nonbusiness hours). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136124\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Have ready access to medications and equipment for resuscitation. An IV infusion of NS 250 to 500 mL should be started, and the doses of antivenin should be delivered by slow injection or via reservoir bottle. Inject the first 1 to 2 mL of antivenin over 3 to 5 minutes with careful observation for the development of a hypersensitivity reaction. The rate of infusion for the remaining antivenin will be regulated by tolerance to the antivenin and the severity of envenomation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136123\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>\n        <i>Micrurus fulvius fulvius </i>(Eastern coral snake) or </b> <b><i>M. f. tener </i></b> <b>(Texas coral snake) envenomation:</b> Treatment of envenomation by an Eastern coral snake (<i>M. f. fulvius</i>) or Texas coral snake (<i>M. f. tener</i>). The antivenin may not be effective in the management of other <i>Micrurus</i> species (Ramos 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136116\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Immediate reactions:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immediate reactions may occur within 30 minutes and may start before needle is withdrawn. Symptoms include apprehension, collapse, cough, cyanosis, dyspnea, facial edema, flushing, laryngeal edema, pruritus, tongue edema, urticaria, vomiting.</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Cardiovascular: Shock</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">Delayed reactions:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Delayed reactions occur 5 to 24 days following administration. Symptoms include arthralgia, edema, fever, lymphadenopathy, malaise, nausea, urticaria, vomiting. Neurological symptoms (eg, amyotrophy, meningism, myasthenia, pain, and peripheral neuritis) may also occur.</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Hypersensitivity: Serum sickness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136126\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications in patients with life- or limb-threatening envenomation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The concomitant administration of opioid analgesics or other analgesics that depress respiration is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Clinicians should be prepared to manage severe, immediate hypersensitivity reactions especially in patients known be allergic to antivenin (<i>Micrurus fulvius</i>) or horse serum (either by history of or as a result of an appropriate sensitivity test).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136114\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Delayed serum sickness: Delayed serum sickness may occur 1 to 3 weeks from administration (especially when large doses used) even with a negative allergic history and absence of reaction to skin test.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Horse serum hypersensitivity: Carefully review allergies and history of exposure to products containing horse serum. History of atopic sensitivity to horses may increase risk of immediate sensitivity reactions. Use with caution in patients with asthma, hay fever, or urticaria.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Beta-blockers: Concomitant use with beta-blockers may prolong and increase the severity of acute anaphylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sedatives/opioids: Use sedatives with extreme caution; concomitant use with opioids or other analgesics that suppress respiration is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: North American coral snake envenomation: Do not administer prophylactically to asymptomatic patients. Clinicians should note that antivenin (<i>Micrurus fulvius</i>) does not neutralize venom of the Arizona or Sonoran coral snake (<i>Micruroides euryoxanthus</i>).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Desensitization: A desensitization protocol is available if sensitivity tests are mildly or questionably positive to reduce risk of immediate severe hypersensitivity reaction. According to the manufacturer, desensitization should be performed when antivenin administration would be lifesaving; however, the risk of anaphylaxis should be weighed against the risks associated with delayed antivenin administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resuscitation precautions: All patients require close monitoring in a setting that has ready access to medications and equipment for resuscitation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin test: The manufacturer recommends that a skin test be performed prior to administration; however, the utility of skin tests to accurately identify patients at risk of early (anaphylactic) or late (serum sickness) hypersensitivity reactions to horse-derived antivenins has been questioned (Klaewsongkram 2009; WHO 2005). The absence of a skin hypersensitivity reaction does not exclude anaphylaxis or hypersensitivity following antivenin administration. False-negative rate for skin testing is 10% with similar agents. Conversely, hypersensitivity is not an absolute contraindication in a significantly envenomated patient.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298766\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136117\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9766&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13265239\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">In general, medications used as antidotes should take into consideration the health and prognosis of the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13359938\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Resolution of symptoms of envenomation or emergence of symptoms of hypersensitivity to the antivenin; respiratory function and oxygenation; urine for hemoglobinuria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F136113\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Antibodies neutralize the venom components, thereby blocking the effects of the Eastern coral snake (<i>Micrurus fulvius</i>) and Texas coral snake (<i>Micrurus tener</i>) venom</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Antivenin (<i>Micrurus fulvius</i>) (Equine origin) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Roodt AR, Paniagua-Solis JF, Dolab JA, et al, &ldquo;Effectiveness of Two Common Antivenoms for North, Central, and South American <i>Micrurus</i> Envenomations,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2004, 42(2):171-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-drug-information/abstract-text/15214622/pubmed\" target=\"_blank\" id=\"15214622\">15214622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA), &quot;Information on the Use of Antivenoms.&quot; Available at <a href=\"http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/ucm094321.htm\" target=\"_blank\">http://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/ucm094321.htm</a>. Last accessed October 31, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klaewsongkram J, &quot;A Role of Snake Antivenom Skin Test From the Allergist's Point of View,&quot; <i>Acta Trop</i>, 2009, 109(1):84-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-drug-information/abstract-text/18929526/pubmed\" target=\"_blank\" id=\"18929526\">18929526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Norris RL, Pfalzgraf RR, and Laing G, &ldquo;Death Following Coral Snake Bite in the United States-First Documented Case (With ELISA Confirmation of Envenomation) in Over 40 Years,&rdquo; <i>Toxicon</i>, 2009, 53(6): 693-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-drug-information/abstract-text/19673084/pubmed\" target=\"_blank\" id=\"19673084\">19673084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramos HR, Vass&atilde;o RC, de Roodt AR, et al. Cross neutralization of coral snake venoms by commercial Australian snake antivenoms. <i>Clin Toxicol (Phila</i>). 2017;55(1):33-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-drug-information/abstract-text/27595162/pubmed\" target=\"_blank\" id=\"27595162\">27595162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanchez EE, Lopez-Johnston JC, Rodriguez-Acosta A, et al, &ldquo;Neutralization of Two North American Coral Snake Venoms With United States and Mexican Antivenoms,&rdquo; <i>Toxicon</i>, 2008, 51(2):297-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-drug-information/abstract-text/18054059/pubmed\" target=\"_blank\" id=\"18054059\">18054059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tanaka GD, Furtado Mde F, Portaro FC, et al, &ldquo;Diversity of Micrurus Snake Species Related to Their Venom Toxic Effects and the Prospective of Antivenom Neutralization,&rdquo; <i>PLoS Negl Trop Dis</i>, 2010, 4(3):e622.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-drug-information/abstract-text/20231886/pubmed\" target=\"_blank\" id=\"20231886\">20231886</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walter FG, Stolz U, Shirazi F, et al, &ldquo;Temporal Analyses of Coral Snakebite Severity Published in the American Association of Poison Control Centers&rsquo; Annual Reports from 1983-2007,&rdquo; <i>Clin Toxicol (Phila)</i>, 2010, 48(1):72-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-drug-information/abstract-text/20070180/pubmed\" target=\"_blank\" id=\"20070180\">20070180</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wood A, Schauben J, Thundiyil J, et al. Review of eastern coral snake (<i>Micrurus fulvius fulvius</i>) exposures managed by the Florida Poison Information Center Network: 1998-2010. <i>Clin Toxicol (Phila)</i>. 2013;51(8):783-788.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/north-american-coral-snake-micrurus-fulvius-antivenom-drug-information/abstract-text/23962099/pubmed\" target=\"_blank\" id=\"23962099\">23962099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, &quot;Guidelines for the Clinical Management of Snake Bites in the South-East Asia Region,&quot; 2005, World Health Organization, Geneva. Available at http://www.searo.who.int/LinkFiles/SDE_mgmt_snake-bite.pdf</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9766 Version 76.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F13265238\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F136142\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F136133\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F136139\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F136134\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15673205\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15673206\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F136122\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F136110\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F49488306\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F136124\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F136123\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F136116\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F136126\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F136114\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298766\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F136117\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13265239\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13359938\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F136113\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9766|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=north-american-coral-snake-micrurus-fulvius-antivenom-patient-drug-information\" class=\"drug drug_patient\">North American coral snake (Micrurus fulvius) antivenom: Patient drug information</a></li></ul></div></div>","javascript":null}